Australia's PharmAust rises after approval to start study

Neurizon Therapeutics

10/04/2024 05:18

** Clinical-stage biotech firm PharmAust's  PAA.AX  shares
rise as much as 7% to A$0.38, biggest intraday pct gain since
April 2
    ** Company says it has received approval from Macquarie
University Human Research Ethics Committee to start an
open-label study of monepantel (MPL) in patients with motor
neurone disease
    ** Study's primary objective is to assess long-term safety
and tolerability of MPL
    ** Stock up ~208% YTD, as of last close

 (Reporting by Neha Soni in Bengaluru)
 ((Neha.Soni@thomsonreuters.com))